China will become the source of Bayer's pharmaceutical innovation

original title: China will become the source of Bayer Pharmaceutical Innovation On February 26th the company reported record sales and earnings before interest, tax, depreciation and amortisation for non-special items, which significantly contributed to the continued growth of our life sciences business, particularly the recent development of our products, said Dr Markin, Chairman of Bayer's Management Board, in a statement.
New products to promote the layout of China Results show that Bayer Group sales in 2014 increased by 5.2% to 42.239 billion euros In 2014, sales in the Healthcare subgroup increased by 5.6% to EUR 19,975 million The increase was largely due to growth in the prescription drug business, which reported slightly higher sales than the same period last year.
Sales in the prescription drug business jumped 11.2 percent, helped by Bayer Healthcare's innovative drugs, the anticoagulant, the eye drug Eylea, the anti-cancer drugs Stivarga and Xofigo, and the pulmonary arterial high-pressure therapy drug Adempa Some of these drugs are not yet available in the Chinese market But there is no doubt that new drugs already on the market in China have "achieved encouraging growth".
"Bayer is focused on innovation," Cornlock, president of Bayer Healthcare China, told Science Daily As long as we continue to introduce innovative products, whether prescription, over-the-counter or animal health products, we will succeed as long as there is demand in the market."
He revealed that Bayer's medium-term goal is to continue to expand the market in China While expanding, try to satisfy China's huge unfilled medical market In the long term, Bayer has a strong long-term commitment to China, which is one of the key markets for Bayer Healthcare In the long run, China will be Bayer's largest market and source of innovation Bayer currently accounts for about 78% and 9% of prescription and over-the-counter drugs in China, respectively (according to 2013 data), and will strengthen its over-the-counter business in China in the future.
"We always welcome opportunities, but they must be sustainable and consistent with the company's long-term development strategy," Conlock said Strategically, we've been looking at what our peers are doing, but it's not about imitating them Currently, Bayer plans to introduce its global product portfolio across various market segments to China, bringing in mature products from foreign markets, representing Bayer's high quality and reliability Highly integrated with the Chinese market Conlock has worked in other countries, he believes that the Chinese market is the most special is the "high speed" China's infrastructure construction has been a great success, life expectancy has been significantly extended, in a relatively short period of time to achieve 95% of the coverage of health care, the initial formation of a universal health care system, compared with other countries, this is a stunning achievement In addition, China's economy is huge, with the world's largest population, GDP growth has attracted the world's attention, in 2010 the world's second largest economy for the first time The third is China's ability to innovate As the Chinese government has created a very innovative macroeconomic environment, the number of patent applications in China has soared, publishing many leading scientific results China is moving in the right direction on the road to encouraging innovation.
In this fast-growing market, Bayer Healthcare has been adhering to a sustainable and robust development rhythm In China, Bayer Healthcare is characterized by high-quality innovation and high integration into the local market, according to Conlock.
"Bayer Healthcare was one of the world's fastest growing pharmaceutical companies in 2014, and Bayer's recently announced portfolio is a global leader In the next five years, 27 new products will be available in China All multinationals are innovating, as Bayer has seen in recent years, as our growth rates have shown In China, Bayer has not only a sales team, but also a team of medical and drug registration, and Bayer Healthcare is based in Beijing, the world's largest plant, and has also established a research and development center in China, Conlock said It can be seen that Bayer is fully integrated into the Chinese domestic market Many companies are working in this direction, but Bayer is one of the front-line companies and has been successful The third is the concern for people Bayer has been named one of the most attractive employers in the pharmaceutical industry For those who can't directly serve or sell products directly from Bayer, Bayer does a number of social welfare programs, such as patient assistance programs, and Bayer offers free medicines to patients in financial difficulties.
There is uncertainty in the Chinese market China is in the stage of medical reform, many policies are in the stage of change Some policy changes have also led to the views of some multinational pharmaceutical companies "The Chinese government is very open and transparent and willing to listen to a wide variety of views to promote the development of the industry, " Mr Conlock said Multinationals are just one of the many stakeholders that governments need to face" He believes that the speed of access to new drugs should be accelerated to facilitate the use of innovative drugs by Chinese patients as soon as possible At present, China's market for drugs approved to market time than the United States and Germany 3-4 years longer But China's Food and Drug Administration is aware of this and is looking for a way to fix it Conlock believes it would be better to be more in line with global regulations and to increase access to medicines This is not only beneficial to multinational pharmaceutical companies, but also to the innovation and development of local pharmaceutical enterprises in China.
The market is changing, and so are laws and regulations Bayer is committed to long-term investment in China and is eager for stable policy and more confidence in the company's decision-making At the same time, Conlock wants to simplify the market access process, "the current provincial access to drugs and hospital access approval mechanisms are more complex." There is no clear solution to this, but I believe these procedures will be simplified in the future."
In Bayer's earnings report, the Group's portfolio focuses on the life sciences business, with all subgroups contributing to record sales and profitability Sales are expected to grow further in 2015, with Bayer Healthcare expected to generate sales of approximately EUR 23 billion Bayer expects sales in the vw health business to grow to 10 billion euros, with the acquisition of the consumer health business also contributing. (Source: Science daily)